In a technology appraisal, the National Institute for Health and Clinical Excellence (NICE) has concluded that ranibizumab is not recommended for the treatment of visual impairment due to diabetic macular oedema.
This conclusion is based on data about cost and effectiveness provided by the manufacturer. NICE’s review team noted important limitations of this data, including the lack of a direct comparison with bevacizumab, a drug cited as an alternative treatment. They considered the views of clinicians and patients.
They recommend that people currently receiving ranibizumab for the treatment of visual impairment due to diabetic macular oedema should have the option to continue treatment until they and their clinicians consider it appropriate to stop.
Users of this guidance should consider:
- Does this guidance developed in accordance with AGREE recommendations?
- Do the estimates of cost-effectiveness, patient utilities and cost-per-QALY thresholds apply to your patients or population?
The full text of this guidance is available from the link below:
Ranibizumab for the treatment of diabetic macular oedema. NICE, 29 November 2011.